LPCUF News Alert Lees Pharmaceutical (LPCUF) 1.1500 09/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lees Pharmaceutical (LPCUF) 1.1500 $LPCUF

Alopecia Pipeline Review Report H2 2014 - 12 Companies & 19 Drug Profiles
M2 - Mon Sep 08, 10:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wmx88j/alopecia) has announced the addition of the "Alopecia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Valeant Pharmaceuticals International, Inc. - Taisho Pharmaceutical Co., Ltd. - AntiCancer, Inc. - Panacea Biotec Limited - C3 Jian, Inc - ProCertus BioPharm Inc. - AndroScience Corporation - Hygeia Therapeutics, Inc. - Kuhnil Pharmaceutical Co., Ltd. - Lee's Pharmaceutical Holdings Limited - vida therapeutics inc. Drug Profiles - DHL-HisZnNa - abatacept - CB-0301 - ProDermaCel - calcitriol - ZK-003 - HYG-430 - HYG-420 - HYG-410 - ASCJ-9 - KI-1104 - Peptide for Alopecia - Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis - V-2248 - Peptide for Alopecia and Chemotherapy Effects - Lipo-4MA - KI-1105 - Drug to Activate P2Y5 Receptor for Alopecia - Small Molecules to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia For more information visit http://www.researchandmarkets.com/research/wmx88j/alopecia

Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6fdl5/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics Companies Mentioned: - Novartis AG - Actelion Ltd - Forest Laboratories, Inc. - Les Laboratoires Servier SAS - Bayer AG - XOMA Corporation - Ahn-Gook Pharmaceutical Co., Ltd. - PhaseBio Pharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - NanoForm Therapeutics Ltd. For more information visit http://www.researchandmarkets.com/research/h6fdl5/idiopathic




Scroll down for more posts ▼

Top 10 Most Recent News Articles

LA Auto Show Partners with PetSet: A Charitable Drive

Updated Category News Views 6

A Unique Partnership Between Cars and Compassion Los Angeles is no stranger to the vibrant blend of culture and cars. This year, the Los Angeles Auto Show decided to steer things to a new lane of compassion by teaming up with PetSet. Now, if you're scratching your head wondering how the automobile world rides in tandem with animal welfare, grab a seat. The 'Road to Home...

Continue Reading
Battery Testing Market to Reach $45 Billion by 2033

Updated Category News Views 141

There's a gold rush happening in the battery testing market, as ambitious as any I've seen in my trading years. The market's taking off faster than a Wall Street trader on a bull market open, projected to skyrocket from $13.03 billion in 2026 to $45.06 billion by 2033. That's a hefty 19.4% compound annual growth rate, a pace that'll have big money and new players...

Continue Reading
ASSA ABLOY Moves Deeper into Brazil, Snaps Up Rometal

Updated Category News Views 131

An Unexpected Power Play in the Aluminum Market Nov. 12, 2026, saw ASSA ABLOY make a calculated move by signing an agreement to acquire Rometal—firmly slotted in Brazil's aluminum sector. Why this gamble? Expansion, baby. You want to plant a flag in burgeoning markets; Brazil ain't a bad choice. This is more than just another deal. This is about gaining ground in a...

Continue Reading
EDB Bolsters AI Governance With Strategic Expertise

Updated Category News Views 98

EDB’s Strategic Move in AI Governance EnterpriseDB (EDB) is throwing some serious weight behind their AI governance strategy by bringing in top-notch talent from CMRD. The buzz? This team didn’t just descend in a parachute—they already have their fingerprints all over the audit infrastructure of EDB’s governance solution. Now, they're officially joining EDB’s...

Continue Reading
Rival's 2026 Index Unveils Braver Challenger Routes

Updated Category News Views 72

Challenger Complacency: When Bold Isn’t Enough Anyone close to the world of aggressive marketing strategy knows that the once-innovative tactics of challenger brands are starting to blend into the wallpaper. Every player and their grandma seems to be singing from the same hymn sheet—earn attention, rub shoulders with creators, launch big splashy promos. As Rival's...

Continue Reading
Brookdale Ready to Share Insights at Stephens Conference

Updated Category News Views 20

Navigating Through the Senior Living Space Oh, the world of senior living—never a dull moment and full of its own nuances. Brookdale Senior Living Inc., right in the thick of it, is prepping to lay it all out at the Stephens Annual Investment Conference this year. Now, they're taking the stage in Nashville on November 19, brimmed with numbers, charts, and possibly a...

Continue Reading
Target's New Board Member: Sally Grimes Joins the Ranks

Updated Category News Views 207

Grimes Joins Target's Board: A Strategic Move In the world of retail, picking the right players for your team can make all the difference. Target's announcement of Sally Grimes stepping onto their Board of Directors has got my attention, and not just because it shakes things up in a boardroom. Grimes is bringing some heavyweight credentials to the table, and her...

Continue Reading
Major Richard Star Act: A Long Overdue Milestone

Updated Category News Views 102

Hard-Won Gains for Our Combat Veterans Washington took a significant stride today—one that feels long overdue as the House of Representatives passed the Major Richard Star Act. This isn't just some routine legislative shuffle; this is the gritty, life-impacting work that cuts to the core of what it means to support those who defended our country. We're talking about...

Continue Reading
Kargo's Tech Boosts Profit on Seafood Supply Chain

Updated Category News Views 11

Revolutionizing Seafood Logistics with Kargo You'd think managing seafood shipments would be a simpler gig than charting ocean routes, but think again. Northern Wind, a major player in seafood processing, just proved the power of tech in an old-school business by partnering with a slick AI outfit called Kargo. Their facility in New Bedford, Massachusetts now magically...

Continue Reading
Oman's Hydrogen Expansion: New Projects, Big Ambitions

Updated Category News Views 88

Oman's Green Hydrogen Strategy Takes Bold Steps Say what you will about Oman, they fancy themselves as the green hydrogen pioneers of the future. Here’s the kicker: they’ve just awarded two heavy-hitting green hydrogen projects in Duqm, and they’re not stopping there. Announced at COP31, this is their third auction’s pièce de résistance, asserting Oman’s green...

Continue Reading

Top 5 Most Recently Viewed Articles

Lattice Semiconductor's New CEO Fuels Stock Surge

Updated Category News Views 98

Lattice Semiconductor Welcomes New Leadership Lattice Semiconductor Corporation (NASDAQ: LSCC) is seeing a notable rise in its share price today. This increase comes in the wake of Ford Tamer being appointed as the new CEO, a decision that has generated optimism among investors. Ford Tamer's Background Ford Tamer arrives with a deep well of experience. He previously held...

Continue Reading
UBS Downgrades Zurich Insurance: Concerns and Market Impact

Updated Category News Views 368

UBS's Downgrade Impact on Zurich Insurance Shares Recently, shares of Zurich Insurance Group (SIX: ZURN) experienced a notable decline after UBS analysts issued a downgrade, changing the stock's rating from 'neutral' to 'sell.' This decision has sent ripples through investor circles and raised concerns among shareholders about the company's future financial performance....

Continue Reading
Annexon Biosciences: Pioneering Neuroinflammatory Treatments

Updated Category News Views 94

Annexon Biosciences to Showcase Latest Developments at Health Care Conference BRISBANE, Calif. — Annexon, Inc. (NASDAQ: ANNX), a pioneering biopharmaceutical company focused on innovative therapies for classical complement-mediated neuroinflammatory conditions, has announced that Douglas Love, the president and chief executive officer, will discuss the company’s...

Continue Reading
Stock Market Update: Marvell, Dell, and Others Face Declines

Updated Category News Views 157

Market Overview and Key Stock Movements On this recent trading session, U.S. stock futures depicted a downward trend, with the Dow futures dropping over 100 points early on. Marvell Technology Inc. Results Shares of Marvell Technology, Inc. (NASDAQ: MRVL) saw a significant drop in pre-market trading after the company provided third-quarter sales guidance that fell short...

Continue Reading
Wolfspeed, Inc. (WOLF) Investors Seek Compensation through Class Action

Updated Category News Views 154

Wolfspeed, Inc. Faces Class Action Lawsuit from Investors Levi & Korsinsky, LLP has announced a class action lawsuit on behalf of investors in Wolfspeed, Inc. This legal action concerns allegations of securities fraud that resulted in significant losses for shareholders. Understanding the Lawsuit The lawsuit primarily seeks to address losses incurred by investors...

Continue Reading